A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Inclusion Criteria: * Inclusion criteria for enrolment * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or/and subjects' Legally Acceptable Representative(s) \[LAR(s)\] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol. * Written informed consent obtained from the subject/LAR(s) of the subject prior to performance of any study-specific procedure. * Subjects who previously participated in study ZOSTER-041 and completed the full 2 dose HZ/su primary vaccination course. * Inclusion criteria for revaccination * Subjects receiving maintenance CIS therapy for the prevention of allograft rejection for a minimum of one month prior to the first revaccination. * Subjects without an episode of allograft rejection within 90 days prior to the first revaccination visit. * Female subjects of non-childbearing potential may be revaccinated. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. * Female subjects of childbearing potential may be revaccinated, if the subject: * has practiced adequate contraception for 30 days prior to revaccination, and * has a negative pregnancy test on the day of revaccination, and * has agreed to continue adequate contraception up to 2 months after completion of the revaccination series. Exclusion Criteria: Exclusion criteria for …